2023
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
MOORE W, LUGOGO N, CHUPP G, MARTIN N, AMBROSE C, COOK W, ACKERT J. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2023, 164: a4-a7. DOI: 10.1016/j.chest.2023.07.073.Peer-Reviewed Original ResearchEffect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti S, Ambrose C, Llanos J, Cook B, Corren J, Colice G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study. Annals Of Allergy Asthma & Immunology 2023, 131: 343-348.e2. PMID: 37263380, DOI: 10.1016/j.anai.2023.05.028.Peer-Reviewed Original ResearchConceptsExacerbation-related hospitalizationsHealthcare utilizationUncontrolled asthmaNAVIGATOR studyAsthma-related healthcare utilizationEffect of tezepelumabPatient healthcare utilizationRecipients of placeboThymic stromal lymphopoietinHealth-related qualityIntensive care daysHuman monoclonal antibodySubcutaneous tezepelumabAsthma controlAsthma exacerbationsLung functionSpecialist visitsEmergency departmentCare daysOverall burdenTezepelumabMAIN OUTCOMEPlaceboAmbulance transportHospitalizationEfficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study
Kraft M, Chupp G, Reeh K, Lindsley A, Cook B, Hunter G, Ambrose C. Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study. 2023, a4751-a4751. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4751.Peer-Reviewed Original Research
2022
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES
CORREN J, WECHSLER M, CHUPP G, AMBROSE C, ROSETI S, HELLQVIST Å, ACKERT J, MARTIN N, COLICE G. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2022, 162: a21-a22. DOI: 10.1016/j.chest.2022.08.018.Peer-Reviewed Original Research
2021
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY
Chupp G, Menzies-Gow A, Ambrose C, Cook W, Kmita K, Lindsley A, Llanos-Ackert J, Colice G, Lugogo N. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY. CHEST Journal 2021, 160: a37-a40. DOI: 10.1016/j.chest.2021.07.078.Peer-Reviewed Original ResearchReductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study
Bourdin A, Menzies-Gow A, Chupp G, Israel E, Hellqvist, Hunter G, Ambrose C, Llanos Ackert J, Colice G, Cook B, Corren J. Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study. 2021, a1203-a1203. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1203.Peer-Reviewed Original ResearchEfficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Griffiths J, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study. Journal Of Allergy And Clinical Immunology 2021, 147: ab249. DOI: 10.1016/j.jaci.2020.12.050.Peer-Reviewed Original Research